Petmed Express Inc

Petmed Express Inc(PETS)の株式分析

$1.220

+0.041 (+3.39%)終値時点

Loading chart…
高値
1.265
始値
1.170
出来高加重平均価格
1.22
出来高
272.24K
時価総額
86.14M
安値
1.170
売買代金
331.68K
EV/EBITDA(TTM)
-0.93

PetMed Express, Inc., doing business as PetMeds, is a direct-to-consumer pet pharmacy. The Company is an online provider of prescription and non-prescription medications, food, supplements, and supplies and has veterinary and pet insurance service partnerships for dogs, cats, and horses. It markets and sells directly to consumers through their Websites, toll-free numbers, and employer benefit partnerships. Its product line contains over 15,000 SKUs of pet medications, health products, foods, and supplies. The Company offers various pet supplies, including beds, crates, stairs and other pet supplies. Its products include Prescription Medications (Rx), Non-Prescription Medications (OTC) and supplies, Pet Foods, Private Label and Holistic Wellness Services. Rx includes heartworm and flea and ticks preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.

www.1800petmeds.com

AI分析 of Petmed Express Inc (PETS)

中立

PetMed Express Inc is not a good buy right now. The current price is $1.22, and the stock has a negative year-to-date change of -63.03%. Additionally, the RSI is at 47.78, indicating that the stock is neither overbought nor oversold, which suggests a lack of strong momentum. The recent acquisition proposal at $3.00 per share indicates potential value, but the company's deteriorating financials, including a net income loss of $6.14 million in the last quarter, pose significant risks.

アナリスト評価(5)

買い
2 買い
2 中立
1 売り
現在: 1.22
安値
—
平均
—
高値
—

Morgan Stanley

2026-09-25

目標株価

—

アンダーウェイト

Morgan Stanley

2025-04-17

目標株価

$3.2

売り

Lake Street

2024-08-07

目標株価

$3.5

中立

Morgan Stanley

2024-06-12

目標株価

$3.5

売り

Lake Street

2024-06-12

目標株価

$7

強い買い

バリュエーション指標

Petmed Express Inc(PETS)の現在の予想PERは16.69で、5年平均は-10.13です。

予想PER

適正
5年平均 P/E
-10.13
現在のP/E
16.69
割高
97.15
割安
-117.42

予想EV/EBITDA

割安
5年平均 EV/EBITDA
7.78
現在のEV/EBITDA
-0.93
割高
14.50
割安
1.07

予想PSR

適正
5年平均 P/S
0.76
現在のP/S
0.17
割高
1.35
割安
0.16

Alphio AI による PETS の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%PETS

$4.12

シナリオ価格

基

基本

基本 · 50%PETS

$3.76

シナリオ価格

弱

弱気

弱気 · 25%PETS

$3.08

シナリオ価格

PETS を保有するクジラ

O

Oaktop Capital Management II, L.P.

+ を保有PETS

-13.50%

3か月リターン

イベントタイムライン

2026-09-21 (ET)

09:00:00

PetMed Express Appoints Tamar Elkeles as Independent Director

2026-09-17 (ET)

09:00:00

PetMed Express Appoints Jeff Willard as CEO

2026-09-14 (ET)

16:30:00

PetMed Express Appoints Andrew Parry as CTO

2026-07-23 (ET)

08:30:00

PetMed Express Enters $37M Sale-Leaseback Agreement with Investor

2026-06-30 (ET)

10:00:00

PetMed Express Receives $3.00 Acquisition Proposal from SilverCape

ニュース

PETS のよくある質問 — Alphio AI が回答

PetMed Express, Inc., doing business as PetMeds, is a direct-to-consumer pet pharmacy. The Company is an online provider of prescription and non-prescription medications, food, supplements, and supplies and has veterinary and pet insurance service partnerships for dogs, cats, and horses. It markets and sells directly to consumers through their Websites, toll-free numbers, and employer benefit partnerships. Its product line contains over 15,000 SKUs of pet medications, health products, foods, and supplies. The Company offers various pet supplies, including beds, crates, stairs and other pet supplies. Its products include Prescription Medications (Rx), Non-Prescription Medications (OTC) and supplies, Pet Foods, Private Label and Holistic Wellness Services. Rx includes heartworm and flea and ticks preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. It operates in the Consumer Non-Cyclicals sector (RETAIL-DRUG STORES AND PROPRIETARY STORES industry).

PetMed Express Inc is not a good buy right now. The current price is $1.22, and the stock has a negative year-to-date change of -63.03%. Additionally, the RSI is at 47.78, indicating that the stock is neither overbought nor oversold, which suggests a lack of strong momentum. The recent acquisition proposal at $3.00 per share indicates potential value, but the company's deteriorating financials, including a net income loss of $6.14 million in the last quarter, pose significant risks.

5 analysts cover PETS: 2 rate it Buy, 2 Hold and 1 Sell.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める